|
1
|
Miller J and Tarter TH: Update on the use
of dutasteride in the management of benign prostatic hypertrophy.
Clin Interv Aging. 2:99–104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Taylor BS, Pal M, Yu J, et al: Humoral
response profiling reveals pathways to prostate cancer progression.
Mol Cell Proteomics. 7:600–611. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lu H, Goodell V and Disis ML: Humoral
immunity directed against tumor-associated antigens as potential
biomarkers for the early diagnosis of cancer. J Proteome Res.
7:1388–1394. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cho-Chung YS: Autoantibody biomarkers in
the detection of cancer. Biochim Biophys Acta. 1762:587–591. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lubin R, Schlichtholz B, Teillaud JL, et
al: p53 antibodies in patients with various types of cancer: assay,
identification and characterization. Clin Cancer Res. 1:1463–1469.
1995.PubMed/NCBI
|
|
6
|
Storr SJ, Chakrabarti J, Barnes A, et al:
Use of autoantibodies in breast cancer screening and diagnosis.
Expert Rev Anticancer Ther. 6:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bachelot T, Ratel D, Menetrier-Caux C, et
al: Autoantibodies to endostatin in patients with breast cancer:
correlation to endostatin levels and clinical outcome. Br J Cancer.
94:1066–1070. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vural B, Chen LC, Saip P, et al: Frequency
of SOX Group B (SOX1, 2, 3) and ZIC2 antibodies in Turkish patients
with small cell lung carcinoma and their correlation with clinical
parameters. Cancer. 103:2575–2583. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jacobs JP, Pettit AR, Shinohara ML, et al:
Lack of requirement of osteopontin for inflammation, bone erosion,
and cartilage damage in the K/BxN model of autoantibody-mediated
arthritis. Arthritis Rheum. 50:2685–2694. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Stromnes IM and Goverman JM:
Osteopontin-induced survival of T cells. Nat Immunol. 8:19–20.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shevde LA, Das S, Clark DW, et al:
Osteopontin: an effector and an effect of tumor metastasis. Curr
Mol Med. 10:71–81. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fedarko NS, Jain A, Karadag A, et al:
Elevated serum bone sialoprotein and osteopontin in colon, breast,
prostate, and lung cancer. Clin Cancer Res. 7:4060–4066.
2001.PubMed/NCBI
|
|
13
|
Hotte SJ, Winquist EW, Stitt L, et al:
Plasma osteopontin: associations with survival and metastasis to
bone in men with hormone-refractory prostate carcinoma. Cancer.
95:506–512. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wai PY and Kuo PC: Osteopontin: regulation
in tumor metastasis. Cancer Metastasis Rev. 27:103–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Forootan SS, Foster CS, Aachi VR, et al:
Prognostic significance of osteopontin expression in human prostate
cancer. Int J Cancer. 118:2255–2261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakata M, Tsuruha JI, Masuko-Hongo K, et
al: Autoantibodies to osteopontin in patients with osteoarthritis
and rheumatoid arthritis. J Rheumatol. 28:1492–1495.
2001.PubMed/NCBI
|
|
17
|
Yokosaki Y, Matsuura N, Sasaki T, et al:
The integrin alpha(9) beta(1) binds to a novel recognition sequence
(SVVYGLR) in the thrombin-cleaved amino-terminal fragment of
osteopontin. J Biol Chem. 274:36328–36334. 1999. View Article : Google Scholar
|
|
18
|
Chung CT, Niemela SL and Miller RH:
One-step preparation of competent Escherichia coli:
trasformation and storage of bacterial cells in the same solution.
Proc Natl Acad Sci USA. 86:2172–2175. 1989.PubMed/NCBI
|
|
19
|
Sardana G, Dowell B and Diamandis EP:
Emerging biomarkers for the diagnosis and prognosis of prostate
cancer. Clin Chem. 54:1951–1960. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bensalah K, Lotan Y, Karam JA, et al: New
circulating biomarkers for prostate cancer. Prostate Cancer
Prostatic Dis. 11:112–120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du H, Masuko-Hongo K, Nakamura H, et al:
The prevalence of autoantibodies against cartilage intermediate
layer protein, YKL-39, osteopontin, and cyclic citrullinated
peptide in patients with early-stage knee osteoarthritis: evidence
of a variety of autoimmune processes. Rheumatol Int. 26:35–41.
2005. View Article : Google Scholar
|
|
22
|
Watanabe M, Uchida K, Nakagaki K, et al:
Anti-cytokine autoantibodies are ubiquitous in healthy individuals.
FEBS Lett. 581:2017–2021. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tomer Y, Sherer Y and Shoenfeld Y:
Autoantibodies, autoimmunity and cancer. Oncol Rep. 5:753–761.
1998.PubMed/NCBI
|
|
24
|
Adler AJ: Mechanisms of T cell tolerance
and suppression in cancer mediated by tumor-associated antigens and
hormones. Curr Cancer Drug Targets. 7:3–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Casiano CA, Mediavilla-Varela M and Tan
EM: Tumor-associated antigen arrays for the serological diagnosis
of cancer. Mol Cell Proteomics. 5:1745–1759. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thalmann GN, Sikes RA, Devoll RE, et al:
Osteopontin: possible role in prostate cancer progression. Cancer
Res. 5:2271–2277. 1999.PubMed/NCBI
|
|
27
|
Bradley SV, Oravecz-Wilson KI, Bougeard G,
et al: Serum antibodies to huntingtin interacting protein-1: a new
blood test for prostate cancer. Cancer Res. 65:4126–4133. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pontes ER, Matos LC, da Silva EA, et al:
Auto-antibodies in prostate cancer: humoral immune response to
antigenic determinants coded by the differentially expressed
transcripts FLJ23438 and VAMP3. Prostate. 66:1463–1473. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi F, Zhang J, Liu D, et al: Preferential
humoral immune response in prostate cancer to cellular proteins p90
and p62 in a panel of tumor-associated antigens. Prostate.
63:252–258. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sreekumar A, Laxman B, Rhodes DR, et al:
Humoral immune response to alpha-methylacyl-CoA racemase and
prostate cancer. J Natl Cancer Inst. 96:834–843. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Leman ES and Getzenberg RH: Biomarkers for
prostate cancer. J Cell Biochem. 108:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
|
